Gewinn- und Verlustrechnung von Gilead Sciences

defenseworld.net2026-10-04 09:02:55

Gilead (NASDAQ: GILD) CEO sells 15,000 shares under a preset plan

What happened Gilead Sciences, Inc. (NASDAQ: GILD) said Chairman and CEO and director Daniel Patrick O'Day sold 15,000 shares on 2026-10-01. The stock went at prices from $147.72 to $148.63 a share, for about $2.22 million total. The filing leaves O'Day with 566,683 shares after the trade. The filing lists the stock as common stock

zacks.com2026-10-02 18:50:54

Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know

Gilead Sciences (GILD) closed the most recent trading day at $144.74, moving 1.87% from the previous trading session.

barrons.com2026-10-01 22:25:00

More Upside Awaits for Gilead Sciences Stock. Stay Invested.

Gilead shares are up 35% since Barron's highlighted them, but our catalysts have yet to fully play out.

zacks.com2026-10-01 10:00:58

Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It

Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

zacks.com2026-09-30 19:00:59

Gilead Sciences (GILD) Declines More Than Market: Some Information for Investors

In the latest trading session, Gilead Sciences (GILD) closed at $149.45, marking a -1.21% move from the previous day.

defenseworld.net2026-09-26 04:31:11

Gilead Sciences, Inc. (NASDAQ:GILD) Stock Has Average Price Target of $158.78 According to Analysts

Gilead Sciences, Inc. (NASDAQ: GILD - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the twenty-nine research firms that are covering the stock, MarketBeat.com reports. Five research analysts have rated the stock with a hold rating, twenty-three have issued a buy rating and one has assigned a strong buy rating to

reuters.com2026-09-25 07:15:33

Genetic discovery yields clues toward reversal of Alzheimer's brain damage

Today we highlight a discovery with potentially important implications for future Alzheimer's research and treatments. We also report on an experimental Gilead therapy showing great promise against a difficult-to-treat form of blood cancer, and an interesting new method for studying cells linked to age-related disorders.

etftrends.com2026-09-25 07:06:19

NTHM's Index Rebalance Puts Thematic Rotation to Work

The latest rebalance of VettaFi's Thematic Rotation Quality Momentum Screened Index (TQRMS), tracked by the NBI Thematic Rotation ETF (NTHM:TSX), reshapes the portfolio around a new set of themes. GLP-1 weight loss drug manufacturers and midstream energy join the index, while battery technology & storage and software-as-a-service (SaaS) exit.

defenseworld.net2026-09-25 03:15:49

Gilead Sciences, Inc. $GILD Stake Decreased by Envestnet Asset Management Inc.

Envestnet Asset Management Inc. reduced its stake in shares of Gilead Sciences, Inc. (NASDAQ: GILD) by 5.9% in the second quarter, according to its most recent filing with the SEC. The fund owned 1,749,512 shares of the biopharmaceutical company's stock after selling 109,500 shares during the period. Envestnet Asset Management Inc. owned approximately

zacks.com2026-09-21 12:56:04

BMY vs GILD: Which Biotech Stock Looks More Attractive Now?

Bristol Myers' growth portfolio and pipeline advances offer multiple ways to offset legacy-product erosion, while valuation and leverage remain key factors.

Erläuterung zur Gewinn- und Verlustrechnung

Erläuterung zur Ertragskraft

Gewinn- und Verlustrechnung von Gilead Sciences, Inc.

Erläuterung zur Gewinn- und Verlustrechnung

Erläuterung zur Ertragskraft